Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
NCT07159750
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Migraine
- Episodic Migraine
- Chronic Migraine, Headache
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Last updated on ClinicalTrials.gov
- September 8, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- University of Miami, Miller School of Medicine · Miami, FL
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.